X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SUVEN LIFE with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs PIRAMAL ENTERPRISES - Comparison Results

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES PIRAMAL ENTERPRISES SUVEN LIFESCIENCES/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 17.8 17.8 100.0% View Chart
P/BV x 3.6 1.1 319.1% View Chart
Dividend Yield % 0.6 1.6 37.3%  

Financials

 SUVEN LIFESCIENCES   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-19
PIRAMAL ENTERPRISES
Mar-19
SUVEN LIFESCIENCES/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs3383,303 10.2%   
Low Rs1691,797 9.4%   
Sales per share (Unadj.) Rs52.1716.5 7.3%  
Earnings per share (Unadj.) Rs6.879.7 8.6%  
Cash flow per share (Unadj.) Rs8.6107.9 7.9%  
Dividends per share (Unadj.) Rs1.5028.00 5.4%  
Dividend yield (eoy) %0.61.1 53.9%  
Book value per share (Unadj.) Rs65.31,477.5 4.4%  
Shares outstanding (eoy) m127.28184.45 69.0%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x4.93.6 136.7%   
Avg P/E ratio x37.132.0 116.0%  
P/CF ratio (eoy) x29.623.6 125.2%  
Price / Book Value ratio x3.91.7 225.0%  
Dividend payout %22.035.1 62.5%   
Avg Mkt Cap Rs m32,272470,292 6.9%   
No. of employees `0001.17.8 13.8%   
Total wages/salary Rs m66122,504 2.9%   
Avg. sales/employee Rs Th6,132.216,899.4 36.3%   
Avg. wages/employee Rs Th611.12,877.7 21.2%   
Avg. net profit/employee Rs Th803.51,879.9 42.7%   
INCOME DATA
Net Sales Rs m6,635132,153 5.0%  
Other income Rs m2423,128 7.7%   
Total revenues Rs m6,877135,281 5.1%   
Gross profit Rs m1,60466,290 2.4%  
Depreciation Rs m2215,202 4.3%   
Interest Rs m3844,097 0.1%   
Profit before tax Rs m1,58720,119 7.9%   
Minority Interest Rs m03,194 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7188,611 8.3%   
Profit after tax Rs m86914,701 5.9%  
Gross profit margin %24.250.2 48.2%  
Effective tax rate %45.242.8 105.7%   
Net profit margin %13.111.1 117.8%  
BALANCE SHEET DATA
Current assets Rs m6,232122,742 5.1%   
Current liabilities Rs m1,490310,810 0.5%   
Net working cap to sales %71.5-142.3 -50.2%  
Current ratio x4.20.4 1,059.1%  
Inventory Days Days8623 374.7%  
Debtors Days Days8339 212.7%  
Net fixed assets Rs m4,043116,904 3.5%   
Share capital Rs m127369 34.5%   
"Free" reserves Rs m8,183272,161 3.0%   
Net worth Rs m8,310272,530 3.0%   
Long term debt Rs m18270,196 0.0%   
Total assets Rs m10,389856,261 1.2%  
Interest coverage x43.11.5 2,960.1%   
Debt to equity ratio x01.0 0.2%  
Sales to assets ratio x0.60.2 413.8%   
Return on assets %8.76.9 127.2%  
Return on equity %10.55.4 194.0%  
Return on capital %19.512.4 157.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,62215,200 37.0%   
Fx outflow Rs m1,7994,889 36.8%   
Net fx Rs m3,82210,312 37.1%   
CASH FLOW
From Operations Rs m356-115,975 -0.3%  
From Investments Rs m-279-8,265 3.4%  
From Financial Activity Rs m-225107,525 -0.2%  
Net Cashflow Rs m-148-16,650 0.9%  

Share Holding

Indian Promoters % 63.4 52.9 119.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 4.0 -  
FIIs % 0.0 26.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 16.5 221.2%  
Shareholders   37,287 93,274 40.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   BIOCON   CADILA HEALTHCARE  AUROBINDO PHARMA  PLETHICO PHARMA  GLENMARK PHARMA  

Compare SUVEN LIFESCIENCES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of Falling Stocks, Tumbling Rupee and Weakening Economy(Podcast)

Another week of slowdown in the markets over fears of a looming slowdown in the domestic and global economy continue.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY19); Net Profit Down 91.4% (Quarterly Result Update)

Apr 30, 2019 | Updated on Apr 30, 2019

For the quarter ended March 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 3 bn (down 91.4% YoY). Sales on the other hand came in at Rs 37 bn (up 23.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

More Views on News

Most Popular

This 60-Year Old Smallcap Company Could Be Our Next Recommendation(The 5 Minute Wrapup)

Aug 12, 2019

My experience at the recent AGM of this smallcap company which has financials of any FMCG major.

Interest Rates Are Low. Buy Solid Dividend Stocks Instead(The 5 Minute Wrapup)

Aug 13, 2019

The dividends paid by these stocks are helpful when interest rates are falling.

My Top 3 Dividend Stocks to Buy Now(Profit Hunter)

Aug 19, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

Smallcaps that Will Outperform in the Market Rebound(Profit Hunter)

Aug 12, 2019

Only These Smallcaps Will Give Historic Returns in the Future.

Chandrayaan 2 Heads to the Moon and It's Good News for These Stocks(The 5 Minute Wrapup)

Aug 14, 2019

Why investors should take note of India's advantage as a low cost satellite launcher...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Aug 23, 2019 (Close)

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES 8-QTR ANALYSIS

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS